Direct dna sequencing of the rat neu oncogene transmembrane domain reveals no mutation in urinary bladder carcinomas induced by n-butyl-n-(4-hydroxybutyl)nitrosamine, n-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide or n-methyl-n-nitrosourea

Tsuneo Masui, Angela M. Mann, Timothy L. Macatee, Emily M. Garland, Takehiko Okamura, Raymond A. Smith, Samuel Monroe Cohen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Epidermal growth factor (EGF) and EGF-related growth factors are present in the urine, and EGF has been identified as a urinary component that enhances urinary bladder tumor formation in rats. Neu oncogene encodes a cell surface receptor similar to the EGF receptor and is known to be activated by a point mutation of DNA that encodes the transrnembrane domain of the neu protein (p185). In this study, we examined the possible mutational activation of neu oncogene in 50 urinary bladder transitional cell carcinomas (TCC) induced in F344 rats by the following carcinogenesis models: (1) 0.05% N-butyl-N-(4-hydroxybutyl)nltrosamine (BBN) (4 weeks) -. 3% uracil (20 weeks); (ii) 0.2% N-[4-(5-nitro-2furyl)-2-thiazolyl]formamide (FANFT) (6 weeks) - 5% sodium saccharin (72 weeks); and (iii) N-methyl-N-nitrosourea (MNU) 20 mg/kg body wt, i.p. twice per week for 4 weeks -. 3% uradil (20 weeks). The DNA sequence around the transmembrane domain of neu gene was amplified by PCR and sequenced. The results showed no mutation within the examined DNA sequences, indicating that neu oncogene is not activated by a point mutation in the transmembrane domain in urinary bladder carcinomas Induced by BBN, FANF or MNU.

Original languageEnglish (US)
Pages (from-to)1975-1978
Number of pages4
JournalCarcinogenesis
Volume12
Issue number10
DOIs
StatePublished - Oct 1 1991

Fingerprint

Nitrosamines
Oncogenes
Epidermal Growth Factor
Methylnitrosourea
Urinary Bladder
Carcinoma
Point Mutation
Mutation
FANFT
erbB-2 Genes
Saccharin
Uracil
Transitional Cell Carcinoma
Inbred F344 Rats
Cell Surface Receptors
Epidermal Growth Factor Receptor
Urinary Bladder Neoplasms
Intercellular Signaling Peptides and Proteins
Carcinogenesis
Urine

ASJC Scopus subject areas

  • Cancer Research

Cite this

Direct dna sequencing of the rat neu oncogene transmembrane domain reveals no mutation in urinary bladder carcinomas induced by n-butyl-n-(4-hydroxybutyl)nitrosamine, n-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide or n-methyl-n-nitrosourea. / Masui, Tsuneo; Mann, Angela M.; Macatee, Timothy L.; Garland, Emily M.; Okamura, Takehiko; Smith, Raymond A.; Cohen, Samuel Monroe.

In: Carcinogenesis, Vol. 12, No. 10, 01.10.1991, p. 1975-1978.

Research output: Contribution to journalArticle

@article{2da81e6decf140a684d656fa11b286e7,
title = "Direct dna sequencing of the rat neu oncogene transmembrane domain reveals no mutation in urinary bladder carcinomas induced by n-butyl-n-(4-hydroxybutyl)nitrosamine, n-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide or n-methyl-n-nitrosourea",
abstract = "Epidermal growth factor (EGF) and EGF-related growth factors are present in the urine, and EGF has been identified as a urinary component that enhances urinary bladder tumor formation in rats. Neu oncogene encodes a cell surface receptor similar to the EGF receptor and is known to be activated by a point mutation of DNA that encodes the transrnembrane domain of the neu protein (p185). In this study, we examined the possible mutational activation of neu oncogene in 50 urinary bladder transitional cell carcinomas (TCC) induced in F344 rats by the following carcinogenesis models: (1) 0.05{\%} N-butyl-N-(4-hydroxybutyl)nltrosamine (BBN) (4 weeks) -. 3{\%} uracil (20 weeks); (ii) 0.2{\%} N-[4-(5-nitro-2furyl)-2-thiazolyl]formamide (FANFT) (6 weeks) - 5{\%} sodium saccharin (72 weeks); and (iii) N-methyl-N-nitrosourea (MNU) 20 mg/kg body wt, i.p. twice per week for 4 weeks -. 3{\%} uradil (20 weeks). The DNA sequence around the transmembrane domain of neu gene was amplified by PCR and sequenced. The results showed no mutation within the examined DNA sequences, indicating that neu oncogene is not activated by a point mutation in the transmembrane domain in urinary bladder carcinomas Induced by BBN, FANF or MNU.",
author = "Tsuneo Masui and Mann, {Angela M.} and Macatee, {Timothy L.} and Garland, {Emily M.} and Takehiko Okamura and Smith, {Raymond A.} and Cohen, {Samuel Monroe}",
year = "1991",
month = "10",
day = "1",
doi = "10.1093/carcin/12.10.1975",
language = "English (US)",
volume = "12",
pages = "1975--1978",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Direct dna sequencing of the rat neu oncogene transmembrane domain reveals no mutation in urinary bladder carcinomas induced by n-butyl-n-(4-hydroxybutyl)nitrosamine, n-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide or n-methyl-n-nitrosourea

AU - Masui, Tsuneo

AU - Mann, Angela M.

AU - Macatee, Timothy L.

AU - Garland, Emily M.

AU - Okamura, Takehiko

AU - Smith, Raymond A.

AU - Cohen, Samuel Monroe

PY - 1991/10/1

Y1 - 1991/10/1

N2 - Epidermal growth factor (EGF) and EGF-related growth factors are present in the urine, and EGF has been identified as a urinary component that enhances urinary bladder tumor formation in rats. Neu oncogene encodes a cell surface receptor similar to the EGF receptor and is known to be activated by a point mutation of DNA that encodes the transrnembrane domain of the neu protein (p185). In this study, we examined the possible mutational activation of neu oncogene in 50 urinary bladder transitional cell carcinomas (TCC) induced in F344 rats by the following carcinogenesis models: (1) 0.05% N-butyl-N-(4-hydroxybutyl)nltrosamine (BBN) (4 weeks) -. 3% uracil (20 weeks); (ii) 0.2% N-[4-(5-nitro-2furyl)-2-thiazolyl]formamide (FANFT) (6 weeks) - 5% sodium saccharin (72 weeks); and (iii) N-methyl-N-nitrosourea (MNU) 20 mg/kg body wt, i.p. twice per week for 4 weeks -. 3% uradil (20 weeks). The DNA sequence around the transmembrane domain of neu gene was amplified by PCR and sequenced. The results showed no mutation within the examined DNA sequences, indicating that neu oncogene is not activated by a point mutation in the transmembrane domain in urinary bladder carcinomas Induced by BBN, FANF or MNU.

AB - Epidermal growth factor (EGF) and EGF-related growth factors are present in the urine, and EGF has been identified as a urinary component that enhances urinary bladder tumor formation in rats. Neu oncogene encodes a cell surface receptor similar to the EGF receptor and is known to be activated by a point mutation of DNA that encodes the transrnembrane domain of the neu protein (p185). In this study, we examined the possible mutational activation of neu oncogene in 50 urinary bladder transitional cell carcinomas (TCC) induced in F344 rats by the following carcinogenesis models: (1) 0.05% N-butyl-N-(4-hydroxybutyl)nltrosamine (BBN) (4 weeks) -. 3% uracil (20 weeks); (ii) 0.2% N-[4-(5-nitro-2furyl)-2-thiazolyl]formamide (FANFT) (6 weeks) - 5% sodium saccharin (72 weeks); and (iii) N-methyl-N-nitrosourea (MNU) 20 mg/kg body wt, i.p. twice per week for 4 weeks -. 3% uradil (20 weeks). The DNA sequence around the transmembrane domain of neu gene was amplified by PCR and sequenced. The results showed no mutation within the examined DNA sequences, indicating that neu oncogene is not activated by a point mutation in the transmembrane domain in urinary bladder carcinomas Induced by BBN, FANF or MNU.

UR - http://www.scopus.com/inward/record.url?scp=0025941675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025941675&partnerID=8YFLogxK

U2 - 10.1093/carcin/12.10.1975

DO - 10.1093/carcin/12.10.1975

M3 - Article

C2 - 1682063

AN - SCOPUS:0025941675

VL - 12

SP - 1975

EP - 1978

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 10

ER -